Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -50.5x - -55.9x | -53.2x |
| Selected Fwd P/E Multiple | -9.2x - -10.2x | -9.7x |
| Fair Value | ₹634.94 - ₹701.77 | ₹668.36 |
| Upside | -47.1% - -41.5% | -44.3% |
| Benchmarks | - | Full Ticker |
| Medico Remedies Limited | - | NSEI:MEDICO |
| Zydus Lifesciences Limited | - | NSEI:ZYDUSLIFE |
| Lupin Limited | - | NSEI:LUPIN |
| GlaxoSmithKline Pharmaceuticals Limited | - | NSEI:GLAXO |
| Alembic Pharmaceuticals Limited | - | NSEI:APLLTD |
| Wockhardt Limited | - | NSEI:WOCKPHARMA |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| MEDICO | ZYDUSLIFE | LUPIN | GLAXO | APLLTD | WOCKPHARMA | |||
| NSEI:MEDICO | NSEI:ZYDUSLIFE | NSEI:LUPIN | NSEI:GLAXO | NSEI:APLLTD | NSEI:WOCKPHARMA | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 39.5% | 15.7% | 30.2% | 5.8% | 1.1% | NM- | ||
| 3Y CAGR | 47.4% | 20.3% | 16.3% | 27.1% | -18.7% | NM- | ||
| Latest Twelve Months | 27.2% | 53.4% | 60.2% | 62.4% | 2.5% | 61.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 4.0% | 18.1% | 3.0% | 20.9% | 12.3% | -4.5% | ||
| Prior Fiscal Year | 5.2% | 11.4% | 2.6% | 18.7% | 6.1% | -21.0% | ||
| Latest Fiscal Year | 5.7% | 19.6% | 9.6% | 17.1% | 9.9% | -16.4% | ||
| Latest Twelve Months | 5.9% | 20.4% | 13.0% | 23.2% | 9.4% | -6.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 38.8x | 13.7x | 17.4x | 40.2x | 18.1x | 73.8x | ||
| Price / LTM Sales | 3.2x | 3.8x | 4.0x | 12.2x | 2.6x | 6.5x | ||
| LTM P/E Ratio | 54.0x | 18.7x | 30.6x | 52.7x | 27.3x | -102.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 18.7x | 30.6x | 54.0x | |||||
| Historical LTM P/E Ratio | -48.2x | -17.9x | -3.6x | |||||
| Selected P/E Multiple | -50.5x | -53.2x | -55.9x | |||||
| (x) LTM Net Income | (1,910) | (1,910) | (1,910) | |||||
| (=) Equity Value | 96,540 | 101,621 | 106,702 | |||||
| (/) Shares Outstanding | 162.5 | 162.5 | 162.5 | |||||
| Implied Value Range | 594.14 | 625.41 | 656.68 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 594.14 | 625.41 | 656.68 | 1,200.20 | ||||
| Upside / (Downside) | -50.5% | -47.9% | -45.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | MEDICO | ZYDUSLIFE | LUPIN | GLAXO | APLLTD | WOCKPHARMA | |
| Value of Common Equity | 4,783 | 849,664 | 876,422 | 453,212 | 165,172 | 195,015 | |
| (/) Shares Outstanding | 83.0 | 1,006.2 | 456.5 | 169.4 | 196.6 | 162.5 | |
| Implied Stock Price | 57.64 | 844.40 | 1,919.70 | 2,675.30 | 840.30 | 1,200.20 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 57.64 | 844.40 | 1,919.70 | 2,675.30 | 840.30 | 1,200.20 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |